Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
about
Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Efficacy and safety of liraglu ...... a from seven phase III trials.
@ast
Efficacy and safety of liraglu ...... a from seven phase III trials.
@en
type
label
Efficacy and safety of liraglu ...... a from seven phase III trials.
@ast
Efficacy and safety of liraglu ...... a from seven phase III trials.
@en
prefLabel
Efficacy and safety of liraglu ...... a from seven phase III trials.
@ast
Efficacy and safety of liraglu ...... a from seven phase III trials.
@en
P2093
P2860
P356
P1433
P1476
Efficacy and safety of liraglu ...... a from seven phase III trials.
@en
P2093
A J Cannon
D D Ørsted
M E Shomali
P2860
P304
P356
10.1111/DME.13185
P577
2016-07-14T00:00:00Z